• Toremifene in Breast Cancer: 20 Years of Clinical Insights

  2026-05-21

  This review synthesizes two decades of data on toremifene, a selective estrogen receptor modulator (SERM), for breast cancer management. It highlights the evolution of endocrine therapy, the importance of biomarker-driven treatment, and comparative outcomes with aromatase inhibitors, providing a foundation for ongoing translational research.

• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetics

  2026-05-20

  This study introduces a streamlined protocol for generating human pluripotent stem cell-derived intestinal organoids with mature drug-metabolizing properties. The findings provide a robust in vitro platform for pharmacokinetic studies, addressing key limitations of animal models and traditional cell lines.

• Protease Inhibitor Cocktail EDTA-Free: Precision Protein Ext

  2026-05-20

  Unlock reproducible, phosphorylation-compatible protein analysis with APExBIO’s EDTA-free Protease Inhibitor Cocktail. Explore advanced troubleshooting, protocol optimization, and real-world use-cases for sensitive downstream workflows—especially where divalent cation integrity is essential.

• Polybrene (Hexadimethrine Bromide): Precision in Viral and D

  2026-05-19

  Polybrene (Hexadimethrine Bromide) 10 mg/mL elevates gene delivery by enhancing viral attachment and broadening cell transduction efficiency, especially for challenging cell lines. Explore actionable workflows, troubleshooting strategies, and the latest experimental insights that set APExBIO’s Polybrene apart in both routine and advanced molecular biology applications.

• Synergistic OXPHOS Disruption by LRPPRC Inhibitors and Dasat

  2026-05-19

  This study reveals that combining LRPPRC inhibition with dasatinib achieves a synergistic blockade of mitochondrial oxidative phosphorylation (OXPHOS) in cancer cells. By targeting both nuclear- and mitochondrial-encoded OXPHOS genes, this dual-genome strategy demonstrates enhanced anti-tumor efficacy and provides a mechanistic rationale for combination therapies in OXPHOS-dependent malignancies.

• DFCP1 Regulates ATGL-Driven Lipid Droplet Lipolysis in Starv

  2026-05-18

  This research clarifies how DFCP1 acts as a nutrient-sensitive regulator of lipid droplet catabolism by modulating the recruitment and retention of ATGL during cellular starvation. The findings offer a mechanistic advance in understanding lipid homeostasis and provide a foundation for more targeted research into metabolic disease mechanisms.

• Protease Inhibitor Cocktail: Enabling Precision in OXPHOS Re

  2026-05-18

  This article examines the mechanistic imperative of robust protease inhibition in translational OXPHOS research, contextualizing the EDTA-Free Protease Inhibitor Cocktail (100X in DMSO) from APExBIO within current advances in dual-genome metabolic targeting. It bridges protein stability workflows with emerging combination therapies—such as LRPPRC inhibition plus dasatinib—offering strategic insights for researchers seeking reproducibility and clinical relevance. Evidence is drawn from recent high-impact studies and internal workflow optimization, with a forward-looking evaluation of limitations and opportunities.

• Acetylcholine Chloride: Optimizing Gut-Brain Cholinergic Ass

  2026-05-17

  Acetylcholine Chloride from APExBIO delivers unmatched precision for dissecting gut-brain cholinergic signaling, as shown in recent epilepsy research. This article translates breakthrough findings into actionable workflows, troubleshooting strategies, and advanced assay guidance for neuroscience and autonomic nervous system studies.

• SPOP Inhibition Boosts STING-Driven Immunotherapy in Melanom

  2026-05-16

  This study uncovers how the E3 ligase SPOP regulates innate immunity in melanoma by targeting STING for degradation, and demonstrates that SPOP inhibitors act as molecular glues, redirecting SPOP to novel neo-substrates. These findings reveal a new strategy for enhancing the efficacy of immunotherapies by modulating protein degradation pathways.

• Neuromedin S (rat): Technical Guidance and Workflow Paramete

  2026-05-15

  Neuromedin S (rat) provides researchers with a chemically defined peptide agonist for targeted activation of neuromedin U receptor signaling in controlled GPCR/G protein studies. It is suitable for fundamental research on energy homeostasis regulation and stress response in rat models, but is not intended for diagnostic, therapeutic, or clinical applications.

• Protease Inhibitor Cocktail EDTA-Free: Enabling Next-Gen Mit

  2026-05-15

  Explore the advanced science behind Protease Inhibitor Cocktail EDTA-Free (100X in DMSO) and its pivotal role in safeguarding proteins for mitochondrial and phosphorylation-sensitive assays. This article bridges latest mechanistic insights with practical assay optimization for high-fidelity proteomics.

• Protease Inhibitor Cocktail: Optimizing Protein Stability Wo

  2026-05-14

  The Protease Inhibitor Cocktail (100X H₂O, EDTA Plus) from APExBIO sets a new benchmark for preserving labile protein complexes during cell and tissue extract workflows. Its broad-spectrum, water-soluble formula ensures robust protein stability and reproducibility—especially in advanced lipid droplet metabolism assays.

• MLF2 Suppresses p53 to Promote Colorectal Cancer Progression

  2026-05-14

  This study identifies myeloid leukemia factor 2 (MLF2) as a novel negative regulator of p53, demonstrating its oncogenic role in colorectal cancer via disruption of USP7-mediated p53 stabilization. The findings reveal potential therapeutic targets within the MLF2–USP7–p53 axis and highlight technical considerations for preserving protein integrity during mechanistic studies.

• Structure–Activity Mapping of Degarelix Analogues for GnRH A

  2026-05-13

  This study systematically explores structural modifications of Degarelix at positions 3, 7, and 8, revealing how subtle changes affect potency and in vivo duration as a GnRH receptor antagonist. The findings advance rational design of peptide antagonists used in hormone secretion inhibition and inform future prostate cancer research.

• GST-Mediated Oxidative Stress Resistance in Megalurothrips u

  2026-05-13

  A recent study elucidates how glutathione S-transferase (GST) contributes to lambda-cyhalothrin resistance in Megalurothrips usitatus by enhancing antioxidant defenses. The research demonstrates that GST inhibition—using diethyl maleate—significantly increases insecticide susceptibility, providing actionable insight for redox regulation and resistance management.

8563 records 17/571 page Previous Next First page 上5页 1617181920 下5页 Last page